Mint Tower Capital Management’s Psyence Biomedical Warrant PBMWW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1K Hold
50,000
– – ﹤0.01% 379
2026
Q2
$1K Hold
50,000
– – ﹤0.01% 341
2026
Q1
$1K Hold
50,000
– – ﹤0.01% 335
2025
Q4
$1K Hold
50,000
– – ﹤0.01% 263
2025
Q3
$1K Hold
50,000
– – ﹤0.01% 200
2025
Q2
$1K Hold
50,000
– – ﹤0.01% 158
2025
Q1
$1K Hold
50,000
– – ﹤0.01% 145
2024
Q4
$1K Hold
50,000
– – ﹤0.01% 141
2024
Q3
$1K Hold
50,000
– – ﹤0.01% 145
2024
Q2
$1K Hold
50,000
– – ﹤0.01% 136
2024
Q1
$4K Buy
+50,000
New +$3.12K ﹤0.01% 165

Other funds holding PBMWW

Mint Tower Capital Management's PBMWW Position: Q3 2026 in Review

Mint Tower Capital Management held its Psyence Biomedical Warrant (PBMWW) position steady in Q3 2026 at 50,000 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #379.

Mint Tower Capital Management first reported a position in PBMWW in Q1 2024 and has held it in 11 quarters since. The position peaked at $4K in Q1 2024. 17 funds tracked by Wall St. Rank hold PBMWW as of Q3 2026.

  • Mint Tower Capital Management held 50,000 shares of Psyence Biomedical Warrant worth $1K as of Q3 2026.
  • Mint Tower Capital Management left its Psyence Biomedical Warrant share count unchanged in Q3 2026.
  • Psyence Biomedical Warrant made up ﹤0.01% of Mint Tower Capital Management's portfolio in Q3 2026, its #379 holding.
  • Mint Tower Capital Management first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 11 quarters since.
  • Mint Tower Capital Management's Psyence Biomedical Warrant position peaked at $4K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q3 2026.

Based on Mint Tower Capital Management's 13F filing for Q3 2026, filed 9 Nov 2026.